omniture
迈威(上海)生物科技有限公司

Latest News

Mabwell to Present Clinical Trial Data of 2 Programs at ESMO Congress 2023

SHANGHAI, July 25, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical compan...

2023-07-26 00:00 1695

Mabwell Announces the NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND

SHANGHAI, July 21, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical compan...

2023-07-22 00:00 4171

Mabwell Announces the NMPA Approval of Novel Trop-2 ADC (9MW2921) for IND

SHANGHAI, July 18, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical compa...

2023-07-19 00:00 2383

Mabwell Announces the U.S. FDA approval of 9MW3811 for IND

SHANGHAI, June 15, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical compan...

2023-06-15 21:00 1970

Mabwell Publishes the Preclinical Study Results on Its Nectin-4 Targeting ADC in A Well-known AACR Journal

SHANGHAI, June 15, 2023 /PRNewswire/ -- Recently, the preclinical study results of 9MW2821, the fir...

2023-06-15 21:00 1979

China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released

SHANGHAI, April 6, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical compan...

2023-04-07 16:34 4210

The World's Second Approved Biosimilars of Denosumab (MAILISHU)

SHANGHAI, April 3, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical compa...

2023-04-03 13:44 1753

Mabwell Launched First in human Clinical Trial of Its Iron Homeostasis Regulating Macromolecular Drug 9MW3011

SHANGHAI, March 14, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical compa...

2023-03-14 23:42 2065

First in Class, Mabwell Announces the TGA Approval of 9MW3811 for IND

SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical compan...

2023-02-28 23:00 1668

$412.5 million! Mabwell Announces Exclusive Licensing Agreement with DISC MEDICINE, INC. for Innovative Drug Candidates of Hematologic Diseases

SAN DIEGO, Jan. 19, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical comp...

2023-01-20 09:50 2155

Mabwell Bioscience Partners with Binnopharm Group to Market 9MW0113, 9MW0321 and 9MW0311 in Russia and Eurasian Economic Union Countries

SHANGHAI and MOSCOW, Dec. 20, 2022 /PRNewswire/ -- Mabwell Bioscience (688062.SH), an innovative bi...

2022-12-20 17:00 1976

Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND

SHANGHAI, Nov. 24, 2022 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical compan...

2022-11-24 21:00 4144
12